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ABSTRACT
Twelve non-repetitive Acinetobacter baumannii
isolates producing the carbapenem-hydrolysing
oxacillinase OXA-58 were recovered from pa-
tients in the same paediatric hospital in Athens,
Greece, between November 2003 and May 2005.
All isolates were clonally related, but the blaOXA-58
gene was not always plasmid-located and there
were variations in the DNA sequences surround-
ing the OXA-58 gene in different isolates. This
study emphasises the importance of the blaOXA-58
carbapenemase gene in conferring carbapenem
resistance among A. baumannii isolates in Greece.
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Carbapenem resistance is now being reported
increasingly in Acinetobacter baumannii isolates [1]
in association with the production of carbapenem-
hydrolysing class D b-lactamases (CHDL) or
oxacillinases that have now emerged worldwide
[2]. Four groups of CHDLs have been identiﬁed to
date in A. baumannii, namely OXA-23, OXA-24,
OXA-51 and OXA-58 [2], although OXA-51 and its
derivatives may be considered to be naturally
occurring b-lactamases in A. baumannii [3,4].
Outbreaks of CHDL-producing A. baumannii iso-
lates have been reported for OXA-24 in Spain [5],
and for OXA-23 in Brazil, South Korea, the UK
and Tahiti [6–9]. In addition, A. baumannii strains
producing OXA-40 appear to be endemic in Spain
and Portugal [10,11].
The OXA-58 CHDL was ﬁrst reported in A.
baumannii strain MAD, which was responsible
for an outbreak of infection in a hospital in
Toulouse, France, during 2003 [12]. Subse-
quently, the blaOXA-58 gene has been identiﬁed
in isolates of Acinetobacter spp. scattered
throughout Europe (Spain, Turkey, Romania)
[13], in Australia [14] and the UK, Argentina
and Kuwait [15]. OXA-58 confers reduced sus-
ceptibility to carbapenems when expressed from
its natural plasmid in a wild-type A. baumannii
strain, and high-level carbapenem resistance
when expressed in an A. baumannii strain with
an over-expressing efﬂux system [16]. The
blaOXA-58 gene identiﬁed in A. baumannii MAD
was located inside an unusual DNA structure
containing IS elements and bracketed by 27-bp
repeated sequences, perhaps resulting from an
homologous recombination event. Similar overall
structures, with variations, have been found in
several blaOXA-58-positive isolates from Europe
[17].
The aim of the present study was to analyse the
spread of carbapenem-resistant A. baumannii iso-
lates recovered from different units of the P. & A.
Kyriakou Children’s Hospital, Athens, Greece,
between November 2003 and October 2005. This
358-bed hospital is one of the two main paediatric
hospitals in Greece, and admits 22 000 patients
annually. During the study period, 93 non-repet-
itive A. baumannii isolates (one per patient) were
isolated and identiﬁed using the API 32GN
system (bioMe´rieux, Marcy-l’Etoile, France). Of
these, 12 isolates were resistant to imipenem,
according to CLSI guidelines [18], all b-lactams,
including meropenem, and all other antibiotics,
including ﬂuoroquinolones and aminoglycosides,
except rifampicin and colistin. Etest strips (AB
Biodisk, Solna, Sweden) combining imipenem
and EDTA did not indicate metallo-b-lactamase
production, but PCR assays with primers speciﬁc
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for CHDL genes (including OXA-23 to -27 and
OXA-40) [13] yielded positive results for the
blaOXA-58 gene. Sequence analysis of the entire
gene revealed perfect identity with the known
blaOXA-58 gene. PCR assays were negative for all
the carbapenem-susceptible isolates tested.
As the OXA-58-producing A. baumannii isolates
were recovered from different units of the P. & A.
Kyriakou Children’s Hospital during an 18-
month period, pulsed-ﬁeld gel electrophoresis
(PFGE) analysis with ApaI was performed to
investigate the clonality of the isolates [19]. The
results showed that the 12 OXA-58-positive iso-
lates corresponded to a single clone that differed
from 30 carbapenem-susceptible isolates that
were also genotyped (data not shown).
Plasmid analysis [20] revealed that ten of the
12 OXA-58-positive isolates harboured two large
plasmids (100 and 80 kb), with isolates 1 and 11
having only a single 80-kb plasmid. A DNA
probe for the blaOXA-58 gene, consisting of a 528-
bp PCR fragment, hybridised with the 100-kb
plasmid in isolates 2–10 and 12, whereas a
slight hybridisation signal was observed with
residual chromosomal DNA for isolates 1 and
11, suggesting that blaOXA-58 was probably
chromosomally-located in those two latter iso-
lates. Transfer of the carbapenem resistance
marker to Escherichia coli and A. baumannii
recipient strains was attempted by conjugation
and electroporation techniques [2], with A.
baumannii isolates 1 and 2 as representative
donors. No transfer occurred from A. baumannii
isolate 1, but transfer occurred from isolate 2
only to an A. baumannii recipient strain. How-
ever, the I-CeuI technique [19] repeatedly failed
to conﬁrm this result, as no positive signal on
the gel was obtained with the blaOXA-58 probe,
but only in the respective wells. Conjugation
and electroporation experiments were unsuc-
cessful in transferring resistance to the E. coli
TOP10 recipient strain, but electroporation of
plasmid extracts from A. baumannii isolate 2 into
the electrocompetent A. baumannii BM4547
recipient strain, which has a hyper-expressed
efﬂux system [16], followed by selection on
plates containing ticarcillin 100 mg ⁄L, yielded A.
baumannii BM4547 (pGR-OXA-58) transformants,
thereby demonstrating the probable plasmid
location of the blaOXA-58 gene in isolate 2 (and
probably also in isolates 3–10). This experiment
was unsuccessful using plasmid extracts of
A. baumannii isolates 1, 11 and 12.
PCR experiments using primers targeting the
blaOXA-58 and IS transposase genes identiﬁed in
blaOXA-58-positive A. baumannii isolates [17] re-
vealed sequence heterogeneity. As indicated in
Fig. 1, the overall structure identiﬁed in isolate 1
2eR 7 1- 2eR 7 2-
SI 2abA
SI ekil-3abA













SI ekil-3abA2eR 7 1- SI 3abAalb 85-AXO
Fig. 1. Schematic arrangement of blaOXA-58-positive structures identiﬁed in Acinetobacter baumannii isolates from Athens,
Greece. (A) Structure identiﬁed in A. baumannii isolate MAD from France. (B) Structure identiﬁed in A. baumannii strain 1.
(C) Structure identiﬁed in A. baumannii strains 2–10. (D) Structure identiﬁed in A. baumannii strains 11 and 12. Genes and
their corresponding transcription orientations are indicated by horizontal arrows. The horizontal dotted line indicates the
sequence separating the truncated ISAba3 element from the Re27–1 repeat sequence. Two different transcription regulator
genes (araC1 and araC2), a threonine efﬂux protein gene (lysE) and an esterase gene (Est) are indicated. Vertical arrows
indicate the two Re27 sequences. Features not indicated in (B) and (C), compared with (A), indicates their absence. Figure is
not to scale.
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was similar to that found in A. baumannii MAD
from France [21], differing only at its right end at
the recombination site (Re27–2). In isolates 11 and
12, the structure was similar, but differed from
isolate 1 at the right end of the ISAba3 element
(Fig. 1). However, the structures identiﬁed in
isolates 2–10 were different, as no ISAba2 and
ISAba3 elements were identiﬁed, indicating that
the structure surrounding the blaOXA-58 gene is
able to evolve over time, even in clonally-related
isolates.
In conclusion, this study showed that a single
clone of carbapenem-resistant A. baumannii iso-
lates had disseminated among several units of a
paediatric hospital during a 7-month period,
suggesting cross-contamination. The blaOXA-58
gene was identiﬁed as the cause of carbapenem
resistance, as has been found in several other
European countries [13]. While this work was in
progress, another report identiﬁed multiple OXA-
58-producing A. baumannii clones in the ICU of
another hospital in Athens, Greece [22]. The
combined data strongly suggest an endemic
situation of multiresistant A. baumannii in the
Athens area. These organisms constitute an
important reservoir of resistance genes in a
country that is already facing an endemic situ-
ation with extended-spectrum b-lactamase and
metallo-b-lactamase genes.
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ABSTRACT
Invasive pneumococcal isolates from three hospi-
tals in Denver, CO, USA were serotyped between
1971 and 2004. Serotype 14 was most common
(13.2%), and other prevalent serotypes (3, 4, 6, 9
and 19) together accounted for 44.1% of the
isolates. All prevalent serotypes and 91.3% of the
total isolates were covered by pneumococcal
polysaccharide vaccine, while 79.1% of prevalent
serotypes and 56.7% of total isolates were covered
by pneumococcal conjugate vaccine. Serotypes 6,
9 and 14 were more common in the ﬁnal decade
than in the ﬁrst decade studied (37.3% vs. 20.2%),
whereas serotypes 3 and 23 were more common
in the ﬁrst decade (18.5% vs. 11.0%).
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Streptococcus pneumoniae causes >60 000 cases of
invasive disease (i.e., infections of normally sterile
sites) annually in the USA (http://www.cdc.gov/
ncidod/dbmd/abcs/survreports/spneu98.pdf),
with the highest rates occurring among young
children [1]. The 23-valent pneumococcal poly-
saccharide vaccines (PPV-23) licensed previously
cover 89% of the serotypes ⁄groups that cause
invasive disease in the USA [2], but fail to protect
children aged <2 years, and do not reduce
nasopharyngeal carriage, which is a source of
transmission [3].
In February 2000, a seven-valent pneumococcal
conjugate vaccine (PCV-7; Prevnar; Wyeth, Madi-
son, NJ, USA) was licensed in the USA for use
among infants and young children [1]. In June
2000, the Advisory Committee on Immunisation
Practices voted to include PCV-7 in the Vaccines
for Children programme [2]. PCV-7 has been
reported to prevent invasive pneumococcal dis-
ease in infants [4,5] and reduces nasopharyngeal
carriage [3,6,7]. It covers the most common
serotypes isolated from the blood or cerebrospinal
ﬂuid of children aged <6 years, but only 50% of
isolates from individuals aged ‡6 years in the
USA [8]. As the prevalence of pneumococcal
serotypes in a community may change with time
[8,9], periodic evaluation of the match between
serotypes causing invasive disease and those
serotypes covered by vaccines is important. The
present study determined serotype secular trends,
and the implications for vaccine efﬁcacy, in
Denver, CO, USA.
Between 1 January 1971 and 31 December 2004,
1490 invasive pneumococcal isolates from three
Denver hospitals (the Colorado General Hospital
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